Trial ID | NM16189 | M37013 | M37002 | M37047 | BM15421 | |||||
---|---|---|---|---|---|---|---|---|---|---|
Safety primary objective of trial? | No†| No†| No¥ | No¥ | No†| |||||
Journal publication: author, journal and year | Chanoine [22], Journal of the American Medical Association (JAMA (2005) | Halpern [23], Diabetes, Obesity and Metabolism (2003) | Hanefeld [25], Diabetes, Obesity and Metabolism (2002) | Kelley [26], Diabetes Care (2002) | Torgerson [24], Diabetes Care (2004) | |||||
CSR research report no. (date of CSR) | 1011426 (2003) | 1002688 (2000) | 1003882 (2001) | 1002743 (2001) | 1008213 (2002) | |||||
Word count (including text and numbers, but not tables) | ||||||||||
Trial document | Pub | CSR | Pub | CSR | Pub | CSR | Pub | CSR | Pub | CSR |
Total number of words in documentϵ | 10,568 | 146,801 | 6,371 | 45,464 | 6,382 | 140,166 | 7,090 | 170,347 | 5915 | 314,277 |
Total number of words relating to safety (% of total) | 1,147 (10.9) | 4,883 (3.3) | 908 (14.3) | 2,664 (5.9) | 638 (10) | 4,964 (3.5) | 707 (10) | 4,150 (2.4) | 387 (6.5) | 6,653 (2.1) |
CSR Moduleɸ supplied by Roche | ||||||||||
I | ✓Π| ✓Π| ✓ | ✓Π| ✓Π| |||||
II | ✓ | ✓ | ✓ | ✓ | * | |||||
III | * | * | * | * | * | |||||
IV | * | * | * | * | * | |||||
V | * | ✓ | ✓ | ✓ | ✓ |